

*The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or part of the content of this announcement.*

## **China Medical and Bio Science Limited**

**中華藥業生物科學有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 8120)**

### **FURTHER DELAY IN PUBLICATION OF RESULTS ANNOUNCEMENT**

#### **Further delay in publication of results announcement**

The publication of the 2008 Final Results will be further delayed for reasons set out in this announcement. The management is in the process of discussing with its auditors in relation to the possible date for the publication of the 2008 Final Results. A further announcement will be made in this regard.

#### **Suspension of trading of shares of the Company**

Trading in the shares of the Company has been suspended from 9:30 a.m., Tuesday, 28 October 2008 and will remain suspended pending the release of the Final Results Announcement.

#### **Further delay in publication of results announcement**

Reference is made to the announcements made by China Medical Bio and Science Limited (the “Company”, together with its subsidiaries, the “Group”) dated 28 October 2008 and 4 November 2008, relating to, among others, the delay in the publication of the final results of the Company for the year ended 31 July 2008.

The board (“Board”) of directors (“Directors”) of the Company announces that the publication of the consolidated audited financial statements of the Company for the year ended 31 July 2008 (the “2008 Final Results”) will be further delayed.

Since the announcement made by the Company dated 4 November 2008, the management have provided the auditors with the valuation report on the valuation reports on the convertible bond and warrants issued by the Company and has also completed the provision of information to the auditors to substantiate the impairment amount of the goodwill, production licenses, property, plant and equipment and land use right. However, the management has yet to provide the following information to the auditors: (i) legal opinion regarding the legal implication of the winding-up petition against the Company by Shantou Xinyuan Trading Co. Limited (as announced in the announcements made by the Company dated 16 May, 16 July, 13 August and 10 September 2008, respectively); (ii) management’s views on the

impact of the auction of certain assets of the Group in Sichuan, The People's Republic of China pursuant to a court order (the "Sichuan Disposal") and documents and reasons to substantiate such views. The management is in the process of preparing required information for the preparation of the announcement on the Sichuan Disposal and is in the process of discussing with its auditors in relation to the possible date for the publication of the 2008 Final Results. A further announcement will be made in this regard.

The Directors have confirmed that they have not dealt in the shares of the Company since 28 September 2008 and have also undertaken not to deal in the shares of the Company until the publication of the Annual Results Announcement.

### **Suspension of trading of shares of the Company**

Trading in the shares of the Company has been suspended from 9:30 a.m., Tuesday, 28 October 2008 pending the release of the financial results of the Company for the year ended 31 July 2008. Further announcement will be made by the Company in this regard.

By Order of the Board  
**China Medical and Bio Science Limited**  
**Liu Yang**  
*Chairman*

Hong Kong, 28 November 2008

*As at the date of this announcement, the Board comprises five executive Directors, namely Ms. Liu Yang (Chairman), Ms. Wong Moon Ha, Dr. Liu Dong Hui, Mr. Wong Sai Wa and Mr. Fang Ming; one non-executive director, namely, Dr. Tan Min; and two independent non-executive Directors, namely Mr. Chan Kin Hang and Dr. Chen Zhuming.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will appear on the GEM website ([www.hkgem.com](http://www.hkgem.com)) for at least seven days after the date of publication and on the website of the Company at [www.irasia.com/listco/hk/chinamedical](http://www.irasia.com/listco/hk/chinamedical).*

\* For identification purpose only